Alpelisib and Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate
Determining the interaction of Alpelisib and Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration of alpelisib with inducers of CYP450 3A4 may reduce the plasma concentrations of alpelisib. The proposed mechanism, based on in vitro data, is increased clearance due to induction of CYP450 3A4, which is one of the routes of metabolism of alpelisib. According to the manufacturer, therapeutic efficacy of alpelisib may be reduced in the presence of potent CYP450 3A4 inducers; however, clinical data are lacking. Data are not available for mild to moderate CYP450 3A4 inducers. MANAGEMENT: Caution is recommended when alpelisib is used with CYP450 3A4 inducers. Pharmacologic effects of alpelisib should be monitored more closely whenever the inducer is added to or withdrawn from therapy. References "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.
Professional:MONITOR: Coadministration of alpelisib with inducers of CYP450 3A4 may reduce the plasma concentrations of alpelisib. The proposed mechanism, based on in vitro data, is increased clearance due to induction of CYP450 3A4, which is one of the routes of metabolism of alpelisib. According to the manufacturer, therapeutic efficacy of alpelisib may be reduced in the presence of potent CYP450 3A4 inducers; however, clinical data are lacking. Data are not available for mild to moderate CYP450 3A4 inducers.
MANAGEMENT: Caution is recommended when alpelisib is used with CYP450 3A4 inducers. Pharmacologic effects of alpelisib should be monitored more closely whenever the inducer is added to or withdrawn from therapy.
- "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.
Generic Name: doravirine / lamivudine / tenofovir
Brand name: Delstrigo
Synonyms: Doravirine, lamivudine, and tenofovir
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Alpelisib-Doribax
- Alpelisib-Doripenem
- Alpelisib-Doripenem Intravenous
- Alpelisib-Dornase Alfa
- Alpelisib-Dornase alfa inhalation
- Alpelisib-Dornase alfa Inhalation, oral/nebulization
- Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate-Alph-E
- Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate-Alph-E-Mixed
- Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate-Alph-E-Mixed 1000
- Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate-Alpha Lipoic Acid
- Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate-Alpha-E
- Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate-Alphagan P